Virax Biolabs Entered Agreement With H.C. Wainwright For $1.45M At The Market Share Offering
Author: Charles Gross | January 22, 2024 06:31pm
On January 22, 2024, Virax Biolabs Group Limited, a Cayman Islands exempted company (the "Company"), entered into an At The Market Offering Agreement (the "Sales Agreement") with H.C. Wainwright & Co., LLC (the "Sales Agent"), acting as the Company's sales agent, pursuant to which the Company may offer and sell, from time to time, through the Sales Agent, its ordinary shares, par value $0.001 per share (the "Ordinary Shares"), having an aggregate offering amount of up to $1,455,029. On January 22, 2024, pursuant to the Sales Agreement, the Company filed a prospectus supplement, including an accompanying base prospectus, dated December 15, 2023, forming a part of its effective registration statement on Form F-3 (File No. 333-275893), initially filed with the Securities and Exchange Commission on December 5, 2023.
Posted In: VRAX